Drs Budoff and Baum discuss the topline results of the ODYSSEY trial presented at the 2018 ACC meeting and hope for easier access to PCSK9 inhibitors for their high-risk patients.

Learn about late-breaking registry data from ACC 2018, comparing patients who underwent His bundle or right ventricular pacing with study authors and HBP pioneers Drs Dandamudi and Vijayaraman.

ODYSSEY, VEST, mSTOPS, CANTOS, and the Black barbershop blood pressure study are among the presentations from the 2018 American College of Cardiology meeting reviewed in this week's podcast.

The co-investigator for the ODYSSEY study of alirocumab discusses which patients will benefit most from the expensive biologic and why the mortality reduction finding comes with qualifiers.

Obesity in young people, type-2 diabetes, the risks of varicose veins, on-pump vs off-pump coronary artery bypass surgery and an ACC preview are the topics discussed in this week's podcast.

Drs Acharya, Friedman, and Klaas discuss when to anticoagulate patients with atrial fibrillation; additional factors that contribute to stroke risk; and treatment options for stroke prevention.

Vegetarian vs Mediterranean diets, a clarithromycin alert, a new stent, best choice of IV fluid, and early work in prevention Type I diabetes are discussed in this week's podcast.

Several images, one underlying pathology--can you identify it? Dr Wharton explains what to look for.

Trials on PCSK9 inhibitors, antiplatelets, anticoagulants, and even catheter ablation of atrial fibrillation are among Drs Harrington and Gibson's picks for what to look for in 2018.

Genetic risk scores and early onset CAD, ECGs in athletes, the ripple effect of weight loss, troponin in sepsis, and fish oil for CVD prevention are the topics discussed in this week's podcast.